CryoPort, Inc. Actuals & Estimates (NASDAQ:CYRX)
This article provides an overview of CryoPort, Inc. (NASDAQ: CYRX) financials, analyst estimates, and stock performance. It details the company's current stock price, market capitalization, earnings, and revenue, alongside analyst price targets and historical highs and lows. The piece also includes frequently asked questions about CYRX stock, including its volatility, dividend policy, and future earnings report date.
Enterprise value to revenue forward of CryoPort, Inc. – NASDAQ:CYRX
This article focuses on the enterprise value to revenue forward metric for CryoPort, Inc. (NASDAQ:CYRX). It presents key financial data and market information related to the company's valuation. The content appears to be a financial snapshot provided by TradingView, detailing various financial aspects and market performance indicators for CYRX.
CryoPort, Inc. $CYRX Shares Bought by Penbrook Management LLC
Penbrook Management LLC significantly increased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 251.6% in the first quarter, adding 132,940 shares. Other institutional investors like AQR Capital Management LLC and Creative Planning also adjusted their positions, with 92.90% of the stock owned by institutions. Despite missing EPS estimates, CryoPort's revenue exceeded expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $15.11, while company insiders have recently sold shares.
Price to book forward of CryoPort, Inc. – NASDAQ:CYRX
This article provides a financial data point for CryoPort, Inc. (NASDAQ: CYRX), specifically its "Price to book forward" value without stating the actual value. It indicates that the data was "Made by humans" and lists various sources for market and reference data, including ICE Data Services and FactSet. The content is primarily a data placeholder from TradingView, focusing on the company's financial overview.
Price to earnings forward of CryoPort, Inc. – MUN:CKX
This page provides financial information for CryoPort, Inc. (CKX) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section within a larger financial data platform.
Cryoport's IntegriCell Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
Cryoport, a leading provider of temperature-controlled supply chain solutions for the life sciences, announced that Verismo Therapeutics has selected its IntegriCell cryopreservation services. This partnership aims to support Verismo's clinical KIR-CAR T cell therapy programs, ensuring the stability and viability of these critical therapeutic cells. The IntegriCell service suite is designed to optimize cryopreservation processes for advanced therapies.
CYRX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for CryoPort, Inc. (CYRX) stock for 2027, based on analyst opinions. It details current stock performance, historical highs and lows, financial metrics like market capitalization, earnings, revenue, and EBITDA, and does not suggest the company pays dividends. The information is presented as general data, not investment advice.
Enterprise value to EBITDA forward of CryoPort, Inc. – GETTEX:CKX
This article focuses on the enterprise value to EBITDA forward for CryoPort, Inc. (GETTEX:CKX). It appears to be a stub or data-point article from TradingView, providing financial metrics for the company within the Air Freight/Couriers sector. The content includes a brief mention of the financial period, value, and change percentages.
CryoPort to Provide IntegriCell Cryopreservation Services for Verismo's Development Programs
Cryoport Systems, a subsidiary of Cryoport, Inc., has been selected by Verismo Therapeutics to provide IntegriCell Cryopreservation services. These services will support Verismo's clinical Kir-Car T cell therapy programs. This announcement highlights Cryoport's role in supplying critical temperature-controlled supply chain solutions for the life sciences industry.
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
Cryoport Systems' IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support its clinical KIR-CAR T cell therapy programs, SynKIR™-110 and SynKIR™-310. This partnership aims to standardize and scale Verismo's cryopreservation processes, ensuring consistency, improving manufacturing efficiency, and de-risking their supply chain for novel solid tumor and B-cell malignancy treatments. IntegriCell's global infrastructure and quality management system will integrate Verismo's existing workflows, assisting their progress through clinical and regulatory milestones.
Cryoport’s IntegriCell selected for Verismo therapy programs By Investing.com
Cryoport, Inc. announced that its IntegriCell cryopreservation services have been chosen by Verismo Therapeutics to support two clinical-stage CAR T cell therapy programs, SynKIR-110 and SynKIR-310, which are both in Phase 1 trials. This partnership will include process development, technology transfer, and clinical cryopreservation services. The news comes as Cryoport’s shares have seen significant growth, and analysts have raised price targets following a strong fiscal Q1 2026 earnings report.
[15-12G] Cryoport, Inc. SEC Filing
Cryoport, Inc. filed Form 15-12G with the SEC to terminate or suspend its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing indicates the termination relies on Rule 12g-4(a)(1) and states that the warrants to purchase common stock, which were previously registered, expired on February 24, 2015. The certification was signed by Robert Stefanovich, Chief Financial Officer, on June 22, 2026.
(CYRX) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Cryoport Inc. (NASDAQ: CYRX) and its movement within quantitative signal sets. It highlights positive near-term sentiment while noting a weak mid-term bias within a long-term strength context. The analysis provides AI-generated signals, including institutional trading strategies and multi-timeframe signal analysis, and identifies compelling upside potential due to the absence of overhead resistance.
Cryoport (CYRX) Proxy Filing Summary
This article summarizes Cryoport's (CYRX) proxy filing, detailing the upcoming annual meeting scheduled for June 6, 2025. Shareholders will vote on the election of six directors, the ratification of Deloitte & Touche LLP as independent auditor, advisory votes on executive compensation, and the frequency of future say-on-pay votes. The summary also lists the recommended director nominees.
Cryoport Inc (CYRX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Cryoport Inc (CYRX), noting its current valuation score is 9.89, ranking 2nd in the Freight & Logistics Services industry. It highlights the company's current P/E ratio of 10.48, which is below its recent high but significantly above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Cryoport Inc (CYRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Cryoport Inc (CYRX) has an earnings forecast score of 8.60, placing it 8th out of 77 in the Freight & Logistics Services industry. Analysts have an average price target of $13.00, with a consensus "Buy" rating based on 10 analysts. The company's expected revenue for the next quarter is $48.21M, and EPS is projected at -$0.19.
Cryoport Inc (CYRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cryoport Inc (CYRX), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 18, 2026, CYRX has a price momentum score of 7.08 and is trading between a resistance level of $16.58 and a support level of $13.59, suggesting suitability for range-bound swing trading. While individual indicators show mixed signals, the overall moving average analysis suggests a "Buy" signal for the stock.
Cryoport Inc (CYRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cryoport Inc (CYRX), listing major shareholders and their proportional holdings, as well as an analysis of shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity with changes in holdings for key investors. Additionally, the article lists related ETFs that include CYRX.
Cryoport Inc (CYRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Cryoport Inc (CYRX). It states that no dividend data or stock split information is available for the company over the past five years. The page also includes current stock information such as market cap, P/E ratio, and recent stock price movements.
Cryoport Inc (CYRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Cryoport Inc (CYRX) for fiscal year 2025. It segments the company's revenue into business lines, including Life Science products, BioLogistics solutions, and BioStorage/Bioservices, and also by geographical regions: Americas, Europe & Middle East & Africa (EMEA), and Asia Pacific. The data highlights that Life Science products and BioLogistics solutions are the primary revenue drivers, with the Americas contributing the largest share regionally.
Cryoport Inc (CYRX) Institutional Confidence
Cryoport Inc (CYRX) has an institutional shareholding score of 10.00, placing it first among 77 companies in the Freight & Logistics Services industry. The latest institutional shareholding proportion is 97.68%, despite a quarter-over-quarter decrease of 16.78%. First Eagle Investment is the largest institutional shareholder, holding 440.09K shares, which represents 1.48% of shares outstanding.
Cryoport Inc (CYRX) Financial Health: Profitability & Balance Sheet Analysis
The article analyzes the financial health of Cryoport Inc (CYRX), giving it a financial score of 7.34, ranking 42 out of 77 in its industry. It highlights the company's robust financial status and average operating efficiency, noting a 16.47% year-over-year increase in quarterly revenue and a 10.28% increase in net profit. However, specific financial data for various categories like cash and equivalents, quality of earnings, operational efficiency, growth potential, and shareholder returns have not been fully disclosed by the company.
Cryoport (CYRX) Stock Fair Value Rises After Analysts Revisit Bioservices Outlook
Analysts have increased Cryoport's (CYRX) fair value per share to US$15.61 from US$13.61, indicating a more positive outlook on the stock's intrinsic worth. This change is driven by recent reports focusing on bioservices operations, with discussion around differentiated offerings, demand patterns, and cost structures influencing execution and risk. Several firms, including Craig-Hallum and KeyBanc, have raised their price targets for CYRX, while Jefferies maintains a Hold rating despite also raising its target, citing potential execution or cost structure risks.
Cryoport chief digital and tech officer sells $507,563 in stock
Cryoport's Chief Digital and Tech Officer, Edward J. Zecchini, sold approximately $507,563 worth of company stock across two days in June 2026. These transactions involved acquiring shares through option exercises at $4.80 each and then selling them at significantly higher market prices. The sales occurred after a period of strong stock performance for Cryoport.
Cryoport chief digital and tech officer sells $507,563 in stock
Edward J. Zecchini, Cryoport's Chief Digital and Tech Officer, recently sold 35,000 shares of company stock for approximately $507,563 after exercising options. The transactions followed strong stock performance and Cryoport (NASDAQ:CYRX) raising its revenue guidance for fiscal 2026, leading to increased price targets from analysts like BTIG, KeyBanc, and Needham. Following these sales, Zecchini directly holds 109,719 shares.
Cryoport chief digital and tech officer sells $507,563 in stock By Investing.com
Edward J. Zecchini, Cryoport's Chief Digital and Tech Officer, recently sold 35,000 shares of the company's common stock for approximately $507,563 after exercising options. The transactions occurred on June 10 and 11, 2026, with shares sold at prices ranging from $14.33 to $15.26. This comes as Cryoport's stock has seen significant performance gains, though InvestingPro analysis suggests it may be overvalued.
Cryoport (CYRX) tech chief exercises 35,000 options and sells shares
Cryoport, Inc.'s Chief Digital and Tech Officer, Edward J. Zecchini, exercised 35,000 stock options at $4.80 per share and subsequently sold all 35,000 shares in open-market transactions on June 10 and 11, 2026, for weighted average prices of approximately $15.23 and $14.47, respectively. Following these transactions, Zecchini directly holds 109,719 shares of Cryoport common stock. The activity is characterized as a routine liquidity event rather than a significant change in ownership, with a net sale value of $507,563.
Analysts Offer Insights on Industrial Goods Companies: CryoPort (CYRX) and Dolby Laboratories (DLB)
Two analysts have issued bullish sentiments on industrial goods companies CryoPort (CYRX) and Dolby Laboratories (DLB). Craig-Hallum maintained a Buy rating on CryoPort with an average price target of $14.83, while Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories with a price target of $85.00, implying a 66.4% upside from current levels. These endorsements suggest optimism within the Industrial Goods sector for both companies.
Cryoport chief digital and tech officer sells $507,563 in stock By Investing.com
Edward J. Zecchini, Cryoport's Chief Digital and Tech Officer, sold approximately $507,563 worth of company stock over two days after exercising options. The insider transactions involved the acquisition and subsequent sale of 35,000 shares, bringing his direct holdings to 109,719 shares. These sales occurred after Cryoport shares saw significant gains and were noted as potentially overvalued by InvestingPro.
CryoPort, Inc. (CYRX) reports Q1 loss, tops revenue estimates
CryoPort, Inc. (CYRX) reported a Q1 loss but exceeded revenue estimates. This suggests the company is growing its top-line performance despite operating at a loss, which is common for growth-oriented companies. Investors will likely focus on continued revenue growth and efforts to improve profitability in future quarters.
[144] Cryoport, Inc. SEC Filing
This SEC filing for Cryoport, Inc. (CYRX) details a proposed sale of 33,600 shares of common stock on June 11, 2026, stemming from the exercise of options under a registered plan, executed via Morgan Stanley Smith Barney LLC. The filing also reports a prior sale of 1,400 shares by Edward Zecchini on June 10, 2026, for $21,323.96. The document provides key figures related to these transactions and outlines the regulatory context of a Form 144 notice.
Cryoport Shareholders Back Board, Auditor and Equity Plan
Cryoport (CYRX) shareholders recently re-elected six directors, including CEO Jerrell W. Shelton, and ratified Deloitte & Touche LLP as the independent auditor. They also approved executive compensation and an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares for equity awards, aiming to attract and retain talent. While analysts currently rate CYRX as a Hold with a $13.00 price target, TipRanks’ AI Analyst indicates a "Neutral" stance due to weak cash flow and profitability concerns, despite a positive earnings call and raised revenue guidance.
Liquidity Mapping Around (CYRX) Price Events
This article provides a detailed liquidity analysis for Cryoport Inc. (NASDAQ: CYRX) based on AI models. It identifies weak near-term sentiment but compelling upside potential due to a lack of resistance levels above the current price. The analysis includes three institutional trading strategies tailored to different risk profiles and a multi-timeframe signal analysis, indicating strong mid and long-term signals.
[144] Cryoport, Inc. SEC Filing
Cryoport, Inc. (CYRX) has filed a Form 144 with the SEC, indicating a proposed sale of 1400 shares of common stock valued at $21,323.96. The shares were acquired through the exercise of options under a registered plan on June 10, 2026. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for this transaction.
Senior VP Robert Stefanovich Sold A Bunch Of Shares In Cryoport
Robert Stefanovich, Senior VP at Cryoport, recently sold US$2.8 million worth of shares at an average price of US$16.27, representing 61% of his total holding. While no insider buys have occurred in the last year, this significant sale at current prices raises some caution. Cryoport insiders collectively own 3.9% of the company.
Trade Alert: Senior VP Of Cryoport Robert Stefanovich Has Sold Stock
Robert Stefanovich, Senior Vice President of Cryoport, recently sold 816 shares of company stock at an average price of $14.50 per share, totaling $11,832. This transaction comes after Stefanovich's previous sale of 10,000 shares in April 2024. While insider selling can sometimes signal a lack of confidence, the overall insider transaction history for Cryoport shows a mix of buying and selling, with analysts providing varied ratings but a general positive price outlook.
Senior VP Robert Stefanovich Sold A Bunch Of Shares In Cryoport
Robert Stefanovich, Senior VP at Cryoport (NASDAQ: CYRX), recently sold shares worth US$2.8 million at an average price of US$16.27, representing 61% of his holding. While insiders own 3.9% of the company, there have been no insider purchases in the last year, only sales, which suggests a cautious outlook. The article highlights that despite some insider ownership, the history of sales warrants careful consideration for potential investors.
Cryoport (NASDAQ: CYRX) investors approve directors, pay and expanded equity plan
Cryoport, Inc. (NASDAQ: CYRX) stockholders approved all proposals at their 2026 Annual Meeting. This included the election of six directors, the ratification of Deloitte & Touche LLP as the independent auditor, advisory approval of executive compensation, and an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares. While most proposals passed with strong support, the equity plan amendment saw a narrower margin, indicating investor sensitivity to potential share dilution.
Cryoport (CYRX) director Linda Baddour receives new stock and option grants
Cryoport, Inc. director Linda Baddour was granted new equity compensation on June 5, 2026, including 10,350 restricted stock rights vesting fully on June 5, 2027, and options to buy 16,077 shares at an exercise price of $15.70. These options will vest monthly over twelve months starting July 5, 2026, and expire on June 5, 2033. Following these grants, Baddour directly holds 68,099 common shares, indicating a neutral impact on the stock.
Cryoport Inc stock (US2289031005): CFO share sale puts focus on Q1 momentum and insider moves
Cryoport Inc. reported better-than-expected Q1 2026 revenue, attracting attention from investors alongside significant insider transactions. The company's CFO sold shares worth approximately $2.76 million, while directors received new equity awards. Cryoport specializes in temperature-controlled supply-chain solutions for the life-sciences industry, focusing on ultra-cold and cryogenic logistics for sensitive materials like cell and gene therapies.
Cryoport (CYRX) director receives restricted stock and option grant
Cryoport, Inc. director Daniel M. Hancock received equity awards, including 10,350 restricted stock rights vesting on June 5, 2027, and options to purchase 16,077 shares at $15.70 per share, expiring on June 5, 2033. These options will vest monthly starting July 5, 2026. Following these grants, Hancock directly holds 69,052 common shares and options for an additional 16,077 shares.
Cryoport Insider Sold Shares Worth $2,756,984, According to a Recent SEC Filing
An insider at Cryoport (CYRX) sold shares valued at $2,756,984, as reported in a recent SEC filing. The company is a provider of integrated, temperature-controlled supply chain solutions for the life sciences sector, with segments in Life Sciences Services and Products. This transaction follows several updates related to the company's equity buyback plan and recent analyst target price revisions.
Cryoport (CYRX) director Hariri granted restricted stock and options
Cryoport director Robert J. Hariri has been granted 10,350 restricted stock rights and options for 16,077 shares of common stock. The restricted stock rights fully vest on June 5, 2027, while the options, with an exercise price of $15.70, will vest monthly beginning July 5, 2026, and expire on June 5, 2033. Following these awards, Hariri directly holds 61,625 shares of common stock in Cryoport (CYRX).
Cryoport CFO Robert Stefanovich sells $2.75m in common stock
Cryoport's (NASDAQ:CYRX) CFO, Robert Stefanovich, sold 169,427 shares of common stock on June 4, 2026, totaling over $2.75 million. This sale occurred while the stock was trading near its 52-week high, after a 122% gain in the past year, and despite recent positive analyst upgrades and increased revenue guidance for fiscal 2026. Following the transaction, he directly holds 109,850 shares.
Cryoport director Mandalam sells $358,452 of company stock
Cryoport director Mandalam Ramkumar sold 23,214 shares of the company's stock for $358,452, with shares trading near a 52-week high after a 122% return over the past year. Despite the sale, Mandalam still holds 67,894 shares and recently acquired restricted stock rights and stock options. The company recently reported better-than-expected revenue in Q1 2026, leading analysts to raise price targets.
Cryoport (CYRX) CFO Stefanovich completes large open-market share sale
Cryoport, Inc.'s Chief Financial Officer, Robert Stefanovich, conducted a significant open-market sale of 169,427 shares of common stock on June 4, 2026. The shares were sold at a weighted average price of $16.2724, with individual trade prices ranging from $16.05 to $16.70. Following this transaction, Stefanovich directly retains ownership of 109,850 Cryoport common shares.
Cryoport Chief Financial Officer Sold Shares Worth Over $2.7M
Cryoport's Chief Financial Officer, Stefanovich Robert, sold 169,427 shares of the company stock, totaling over $2.7 million. The shares were sold at a weighted average price of $16.2724, with individual transactions ranging from $16.05 to $16.70. Following this sale, Robert directly owns 109,850 shares of Cryoport.
Cryoport (CYRX) director Mandalam sells 23,214 shares, receives new stock awards
Cryoport director Ramkumar Mandalam sold 23,214 common shares at a weighted average price of $15.4412 per share on June 8, 2026. Prior to this sale, on June 5, 2026, he received 10,350 restricted stock rights vesting in June 2027 and options for 16,077 shares with an exercise price of $15.70. Following these transactions, Mandalam directly holds 67,894 common shares of Cryoport.
CYRX (NASDAQ: CYRX) Form 144 shows 23,214 vested shares for potential sale
Cryoport, Inc. (CYRX) filed a Form 144 indicating a proposed sale of 23,214 shares of common stock, stemming from restricted stock vesting under a registered plan. The transaction date is listed as June 6, 2026, and Morgan Stanley Smith Barney LLC is named as the broker-dealer. This filing is a routine disclosure for affiliated holders intending to sell vested shares.
Cryoport (CYRX) affiliate files Form 144 listing several option lots for resale
A Cryoport (CYRX) affiliate has filed a Form 144, indicating proposed sales of common stock derived from multiple stock option lots. The filing details seven option lots ranging from 5,000 to 53,334 shares, with grant dates spanning from June 2021 to December 2024. This Form 144 serves as a regulatory notice of intent to sell and does not confirm completed transactions or disclose sale proceeds or timing.
